Biocon Biologics, a subsidiary of the renowned pharmaceutical company Biocon Ltd, has recently made significant leadership appointments that are crucial to the organization’s transformation and realization of its vision to become a global leader in biosimilars.
According to a company statement, Rhonda Duffy has been designated as Chief Operating Officer (COO) and will be responsible for overseeing manufacturing, quality, and supply chain management. With an impressive track record of over 30 years in the global pharmaceutical industry, Duffy brings invaluable expertise to her new role.
Dr Sandeep Athalye, who has served as Chief Medical Officer at Biocon Biologics for over six years, has been promoted to the position of Chief Development Officer. In this capacity, he will lead key areas including CMC (Chemistry, Manufacturing, and Controls), Clinical Development, and Medical and Regulatory Affairs.
David Gibson, formerly associated with GlaxoSmithKline (GSK), has joined Biocon Biologics to take charge of all licensing, strategic partnering, and business development activities as the Global Head of Business Development.
Stephanie Wasco has been appointed as the Head of Communications – Advanced Markets. Her primary responsibility will be leading Corporate and Marketing Communications, as well as Product Branding in Advanced Markets, such as the US and Europe.
Apart from these crucial leadership appointments, Biocon Biologics has also brought in global talent to strengthen various functions, including Manufacturing Science and Technology (MSAT), Clinical Development, Finance, HR, Legal, and Compliance.
Shreehas Tambe, the CEO and Managing Director of Biocon Biologics expressed confidence in the new leadership team, highlighting their wealth of global experience. He emphasized that these appointments would enable the organization to prepare for the future and seamlessly integrate the recently acquired global biosimilar business from Viatris. This integration will enhance performance, reliability, and sustainability, ensuring the delivery of high-quality and affordable biosimilars to millions of patients worldwide.
